MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Reco ...
Multiple Sclerosis
Drug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia®
Charite University, Berlin, Germany
NeuroCure Clinical Research Center, Charite, Berlin
Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis
Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with ...
To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs statusNAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested. To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To m ...